Clinical Trial: Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Brief Summary: The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.
Detailed Summary:
Sponsor: Ziopharm
Current Primary Outcome: Response Rate [ Time Frame: 6 months ]
Original Primary Outcome:
Current Secondary Outcome: toxicities [ Time Frame: 6 months ]
Original Secondary Outcome:
Information By: Ziopharm
Dates:
Date Received: January 10, 2007
Date Started: December 2006
Date Completion:
Last Updated: July 18, 2012
Last Verified: July 2012